![]() |
市場調查報告書
商品編碼
1385343
停經後骨質疏鬆症治療市場規模 - 按藥物類型(雙磷酸鹽、荷爾蒙替代療法 (HRT))、給藥途徑、配銷通路、全球預測(2023-2032)Postmenopausal Osteoporosis Treatment Market Size - By Drug Type (Bisphosphonates, Hormone Replacement Therapy (HRT)), Route of Administration, Distribution Channel, Global Forecast (2023-2032) |
由於全球政府支持性措施和醫療保健政策的激增,預計 2023 年至 2032 年停經後骨質疏鬆症治療市場規模的CAGR為 4.6%。補貼醫療服務、藥物負擔能力和支持性研發計畫的湧入正在創造一個有利於有效骨質疏鬆症管理的環境。此外,政府驅動的法規和指南也顯著增加,以確保品質標準和病人安全,同時促進創新治療方法的整合。
此外,行業參與者不斷努力透過開發先進的學名藥配方和設備工程來加強其市場地位,以提高患者獲得關鍵治療選擇的機會,這將增強行業前景。例如,2023 年11 月,Teva Pharmaceutical Industries Ltd. 的美國子公司Teva Pharmaceuticals Inc. 獲得批准銷售學名藥Forteo (R)1,這是一種含有特立帕肽的注射劑,用於治療某些男性和女性患者的骨質疏鬆症。
停經後骨質疏鬆症治療產業按藥物類型、給藥途徑、配銷通路和區域細分。
根據藥物類型,荷爾蒙替代療法 (HRT) 領域的市場佔有率預計在 2023 年至 2032 年間將獲得 4.8% 的CAGR。HRT 已成為停經後骨質疏鬆症的有效治療方法,因為它有助於維持骨密度、減少骨折風險並管理症狀。此外,擴大採用荷爾蒙替代療法來治療停經後女性,再加上持續不斷的配方研發工作,將推動該細分市場的擴張。
在配銷通路方面,預計到2032年,醫院藥房領域的停經後骨質疏鬆症治療行業將實現3.7%的成長率。醫院藥房是骨質疏鬆症藥物的重要分銷點,以確保處方治療的可及性。從醫院藥房獲取藥物的便利性以及醫院專家醫療保健專業人員的可用性更高,將有助於該細分市場的成長。
從地區來看,在人口老化和骨質疏鬆症管理意識不斷提高的推動下,到 2032 年,亞太地區停經後骨質疏鬆症治療市場預計將呈現 5.2% 的成長率。根據 NCBI 2023 年發布的估計,到 2050 年,亞洲將佔骨質疏鬆症引起的所有骨折的一半以上,其中停經後婦女是最脆弱的。該地區停經後婦女骨質疏鬆症盛行率不斷上升,預計將刺激對先進療法的需求。此外,不斷增加的醫療保健支出、改善的醫療保健基礎設施和政府措施將進一步促進該地區停經後骨質疏鬆症治療的採用。
Postmenopausal Osteoporosis Treatment Market size is estimated to depict 4.6% CAGR from 2023 to 2032 attributed to the surge in supportive government initiatives and healthcare policies worldwide. The influx of subsidized healthcare services, medication affordability, and supportive R&D initiatives are creating an environment conducive to effective osteoporosis management. Additionally, there has been significant increase in government-driven regulations and guidelines for ensuring quality standards and patient safety while promoting the integration of innovative treatment approaches.
Furthermore, the rising efforts by industry players on strengthening their market position through the development of advanced generic formulations and device engineering to enhance patient access to crucial treatment options will augment the industry outlook. For instance, in November 2023, Teva Pharmaceuticals Inc., a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. received approval to market the generic version of Forteo®1, an injectable containing teriparatide, prescribed to treat osteoporosis in certain male and female patients.
The postmenopausal osteoporosis treatment industry is segmented into drug type, route of administration, distribution channel, and region.
Based on drug type, the market share from the hormone replacement therapy (HRT) segment is anticipated to gain 4.8% CAGR between 2023 and 2032. HRT has emerged as an effective treatment approach for postmenopausal osteoporosis as it helps to maintain bone density, reduce fracture risk, and manage symptoms. Additionally, the increasing adoption of hormone replacement therapies to treat postmenopausal women coupled with the ongoing R&D efforts for formulations will propel the segment expansion.
In terms of distribution channel, the postmenopausal osteoporosis treatment industry from the hospital pharmacies segment is estimated to record 3.7% growth rate through 2032. Hospital pharmacies serve as crucial distribution points for osteoporosis medications for ensuring accessibility to prescribed treatments. The convenience of obtaining medications from hospital pharmacies and the higher availability of expert healthcare professionals at hospitals will contribute to the segment growth.
Regionally, the Asia Pacific postmenopausal osteoporosis treatment market is set to exhibit 5.2% growth rate through 2032 driven by the aging population and increasing awareness of osteoporosis management. According to NCBI estimations published in 2023, Asia will account for more than half of all fractures caused by osteoporosis by 2050, with postmenopausal women being the most vulnerable. This rising prevalence of osteoporosis among postmenopausal women across the region is expected to fuel the demand for advanced therapies. Moreover, the rising healthcare expenditure, improving healthcare infrastructure, and government initiatives will further boost the adoption of postmenopausal osteoporosis treatments in the region.